Armata Pharmaceuticals (ARMP) Assets Average (2014 - 2026)

Armata Pharmaceuticals has disclosed Assets Average across 13 years of filings, most recently posting $73.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $73.3 million, down 15.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.3 million (down 15.55% YoY), and the FY2025 annual result was $81.7 million, down 11.62% from the prior year.
• Assets Average came in at $73.3 million for Q1 2026 at Armata Pharmaceuticals, down from $83.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $114.3 million in Q2 2024 to a low of $73.3 million in Q1 2026.
• The 5-year median for Assets Average is $96.9 million (2022), against an average of $96.2 million.
• Across the five-year window, Assets Average soared 113.15% in 2022 and dropped 26.51% in 2025, its largest moves.
• Armata Pharmaceuticals' Assets Average stood at $94.4 million in 2022, then gained by 11.87% to $105.6 million in 2023, then slipped by 12.53% to $92.3 million in 2024, then fell by 9.9% to $83.2 million in 2025, then decreased by 11.85% to $73.3 million in 2026.
• The last three Assets Average figures came in at $73.3 million (Q1 2026), $83.2 million (Q4 2025), and $85.2 million (Q3 2025), per Business Quant data.